319 related articles for article (PubMed ID: 15644013)
1. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
Green C; Dinnes J; Takeda A; Shepherd J; Hartwell D; Cave C; Payne E; Cuthbertson BH
Health Technol Assess; 2005 Mar; 9(11):1-126, iii-iv. PubMed ID: 15774234
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain].
Sacristán JA; Prieto L; Huete T; Artigas A; Badia X; Chinn C; Hudson P
Gac Sanit; 2004; 18(1):50-7. PubMed ID: 14980173
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Green C; Dinnes J; Takeda AL; Cuthbertson BH
Int J Technol Assess Health Care; 2006; 22(1):90-100. PubMed ID: 16673685
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany.
Neilson AR; Burchardi H; Chinn C; Clouth J; Schneider H; Angus D
J Crit Care; 2003 Dec; 18(4):217-27. PubMed ID: 14691895
[TBL] [Abstract][Full Text] [Related]
8. Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.
Frampton JE; Foster RH
Pharmacoeconomics; 2004; 22(7):445-76. PubMed ID: 15137883
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure.
Riou França L; Launois R; Le Lay K; Aegerter P; Bouhassira M; Meshaka P; Guidet B
Int J Technol Assess Health Care; 2006; 22(1):101-8. PubMed ID: 16673686
[TBL] [Abstract][Full Text] [Related]
10. Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
Sadique MZ; Grieve R; Harrison DA; Cuthbertson BH; Rowan KM
Crit Care; 2011; 15(5):R228. PubMed ID: 21943177
[TBL] [Abstract][Full Text] [Related]
11. Management challenge with drotrecogin alfa (activated).
Vanscoy GJ
Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S23-9. PubMed ID: 11885411
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of drotrecogin alfa (activated).
Tsitanidis J
Crit Care Med; 2003 Sep; 31(9):2414-5; author reply 2415. PubMed ID: 14501983
[No Abstract] [Full Text] [Related]
13. Drotrecogin alfa (activated) for severe sepsis.
Drug Ther Bull; 2006 Jan; 44(1):5-8. PubMed ID: 16425899
[TBL] [Abstract][Full Text] [Related]
14. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
[TBL] [Abstract][Full Text] [Related]
15. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
[TBL] [Abstract][Full Text] [Related]
16. Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question.
Banks SM; Gerstenberger E; Eichacker PQ; Natanson C
Crit Care Med; 2003 Jan; 31(1):308-9. PubMed ID: 12545035
[No Abstract] [Full Text] [Related]
17. Drotrecogin alfa's impact on intensive care workload in real life practice: a propensity score approach.
Riou França L; Payet S; Le Lay K; Launois R
Value Health; 2008 Dec; 11(7):1051-60. PubMed ID: 18494757
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Kalil AC; LaRosa SP
Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of activated protein C in real-life clinical practice.
Dhainaut JF; Payet S; Vallet B; França LR; Annane D; Bollaert PE; Le Tulzo Y; Runge I; Malledant Y; Guidet B; Le Lay K; Launois R;
Crit Care; 2007; 11(5):R99. PubMed ID: 17822547
[TBL] [Abstract][Full Text] [Related]
20. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
